

# Technical Data Sheet

## InVivoSIM anti-human PD-1 (Tislelizumab Biosimilar)



[bioxcell.com](http://bioxcell.com)

**Attention:** Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at <https://bioxcell.com/terms-and-conditions>.

### Lot Specific Information

Lot Number: Lot Specific\*  
Volume: Lot Specific\*  
Concentration: Lot Specific\* (generally 4 to 11 mg/ml) \*  
Total Protein: Lot Specific\*

\*This information will be noted on the certificate of analysis that ships with this product.

Product Website Link: <https://bioxcell.com/invivosim-anti-human-pd-1-tislelizumab-biosimilar-sim0038>

### Product Information

Catalog Number: SIM0038  
Clone: Tislelizumab  
Isotype: Human IgG4,  $\kappa$   
Recommended Isotype Control(s): RecombiMAb human IgG4 (S228P/R409K) isotype control, anti-hen egg lysozyme  
Recommended Dilution Buffer: InVivoPure pH 7.0 Dilution Buffer  
Mutations: S228P/E233P/F234V/L235A/D265A/R409K  
Immunogen: Human PD-1  
Reported Applications: Blocking of PD-1/PD-L signaling  
Functional assays  
ELISA  
Formulation: PBS, pH 7.0  
Contains no stabilizers or preservatives  
Endotoxin:  $\leq 0.5$  EU/mg ( $\leq 0.0005$  EU/ $\mu$ g)  
Determined by LAL assay  
Purity:  $\geq 95\%$   
Determined by SDS-PAGE  
Sterility: 0.2  $\mu$ m filtration  
Production: Purified from cell culture supernatant in an animal-free facility  
Purification: Protein A  
Aggregation:  $< 5\%$   
Determined by SEC  
RRID:  
Molecular Weight: 150 kDa

### Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

### Description

This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Tislelizumab making it ideal for research use. This Tislelizumab biosimilar reacts with human PD-1 (programmed death-1) also known as CD279.

PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdc1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdc1 mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1's structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In experimental models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. The structure of Tislelizumab has been modified to maximally inhibit the binding of PD-1 to PD-L1 and minimize the binding of Tislelizumab to Fcγ receptors. The epitope of Tislelizumab is formed on the CC' loop of the front β sheet face of PD-1, which is innovative among anti-PD-1 antibodies; in comparison, other PD-1 antibodies, like Nivolumab and Pembrolizumab, bind to the N-terminal region and the C'D loop of PD-1, respectively. Tislelizumab is able to bind to human PD-1 with high specificity and affinity, with the disassociation constant being 0.15 nmol/L. At the 5 mg/kg dose, PD-1 receptor occupancy is >90%. In clinical studies, Tislelizumab has shown preliminary anti-tumor effects in various solid tumors.

## Storage

Store at the stock concentration at 4°C . **Do not freeze.**

It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at <https://bioxcell.com/faqs>.

## Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

## Application References


For a complete list of references, visit

[https://bioxcell.com/inivosim-anti-human-pd-1-tislelizumab-biosimilar-sim0038?utm\\_source=cr9k1b#tab\\_references](https://bioxcell.com/inivosim-anti-human-pd-1-tislelizumab-biosimilar-sim0038?utm_source=cr9k1b#tab_references) or scan the QR code below.



## Binding Validation

Validation data shown below confirms that this clone binds to its target antigen. For lot specific binding validation data, e-mail [technicalservice@bioxcell.com](mailto:technicalservice@bioxcell.com).



**Bio X Cell, LLC**

<https://bioxcell.com>

+1-866-787-3444

[customerservice@bioxcell.com](mailto:customerservice@bioxcell.com)

*Conditions: For research use only. Not for human use. Not for use in diagnostic or therapeutic procedures.*

*Not for resale.*

**Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © Bio X Cell, LLC**